Short answer
MIMEDX GROUP, INC. (MDXG) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration.
MIMEDX GROUP, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration
- $300.0 million first-lien senior secured term loan financing, increasing leverage and replacing MiMedx’s existing credit facility
- Sanara stockholders controlling approximately 38.9% of voting power committed to support the transaction
- Closing requires Sanara stockholder approval, HSR clearance, SEC-effective Form S-4, Nasdaq listing approval, and other customary conditions
- Termination fees: Sanara $22,540,785 to MiMedx; MiMedx $9,660,336 to Sanara under specified circumstances
Item 7.01 · Regulation FD Disclosure
- Proposed MiMedx–Sanara merger remains subject to stockholder approval, regulatory clearances, financing, and other closing conditions
- Management highlights potential combined surgical revenue and Adjusted EBITDA margin benefits, without quantified figures here
- Transaction timing and realization of synergies remain uncertain, with termination or delayed-closing risks
- SEC Form S-4 registration statement and Sanara proxy statement/prospectus expected to provide definitive deal terms
- Investors should review future SEC filings before voting or making investment decisions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MIMEDX GROUP, INC. 8-K filings
Get the next MDXG 8-K as it lands
Follow MDXG for push alerts, or ask the research agent what this filing means.